User menu

EANM procedure guidelines for PET brain imaging using [(18)F]FDG : version 2

Bibliographic reference Varrone, Andrea ; Asenbaum, Susanne ; Vander Borght, Thierry ; Booij, Jan ; Nobili, Flavio ; et. al. EANM procedure guidelines for PET brain imaging using [(18)F]FDG : version 2. In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 36, no. 12, p. 2103-2110 (2009)
Permanent URL
  1. Bartenstein P, Asenbaum S, Catafau A, et al. European Association of Nuclear Medicine procedure guidelines for brain imaging using [(18)F]FDG. Eur J Nucl Med Mol Imaging 2002;29:BP43–8.
  2. Kuwert T, Bartenstein P, Grünwald F, et al. Clinical value of positron emission tomography in neuromedicine. Position paper on results of an interdisciplinary consensus conference. Nervenarzt 1989;69:1045–160.
  3. Asenbaum S. Guideline for the use of FDG PET in Neurology and Psychiatry. Austrian Society of Nuclear Medicine 2001. .
  4. Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med 1998;39:1302–5.
  5. Society of Nuclear Medicine Brain Imaging Council. Ethical clinical practice of functional brain imaging. J Nucl Med 1996;37:1256–9.
  6. Messa C, Fazio F, Costa DC, Ell PJ. Clinical brain radionuclide imaging. Semin Nucl Med 1995;25:111–43.
  7. Setani K, Schreckenberger M, Sabri O, et al. Comparison of different methods for attenuation correction in brain PET: effect on the calculation of the metabolic rate of glucose. Nuklearmedizin 2000;39:50–5.
  8. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302–16.
  9. Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol 2007;80:S160–7.
  10. Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med 2008;49:390–8.
  11. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734–46.
  12. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778–85.
  13. Henry TR, Votaw JR. The role of positron emission tomography with [18F]fluorodeoxyglucose in the evaluation of the epilepsies. Neuroimaging Clin N Am 2004;14:517–35.
  14. Van Paesschen W, Dupont P, Sunaert S, Goffin K, Van Laere K. The use of SPECT and PET in routine clinical practice in epilepsy. Curr Opin Neurol 2007;20:194–202.
  15. Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26:912–21.
  16. Eckert T, Tang C, Ma Y, Brown N, Lin T, Frucht S, et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord 2008;5:727–33.
  17. Hasselbalch SG, Knudsen GM, Videbaek C, et al. No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes 1999;48:1915–21.
  18. Cranston I, Marsden P, Matyka K, et al. Regional differences in cerebral blood flow and glucose utilization in diabetic man: the effect of insulin. J Cereb Blood Flow Metab 1998;18:130–40.
  19. Spanaki M. V., Siegel H., Kopylev L., Fazilat S., Dean A., Liow K., Ben-Menachem E., Gaillard W. D., Theodore W. H., The effect of vigabatrin ( -vinyl GABA) on cerebral blood flow and metabolism, 10.1212/wnl.53.7.1518
  20. Berding G, Odin P, Brooks DJ, et al. Resting regional cerebral glucose metabolism in advanced Parkinson´s disease studied in the off and on conditions with [18F]FDG-PET. Mov Disord 2001;6:1014–22.
  21. Feigin A., Fukuda M., Dhawan V., Przedborski S., Jackson-Lewis V., Mentis M.J., Moeller J.R., Eidelberg D., Metabolic correlates of levodopa response in Parkinson's disease, 10.1212/wnl.57.11.2083
  22. Ruotsalainen U, Suhonen-Polvi H, Eronen E, et al. Estimated radiation dose to the newborn in FDG-PET studies. J Nucl Med 1996;37:387–93.
  23. Wu T-H, Huang Y-H, Lee JJS, Wang S-Y, Wang S-C, Su C-T, et al. Radiation exposure during transmission measurements: comparison between CT- and germanium-based techniques with a current PET scanner. Eur J Nucl Med Mol Imaging 2004;31:38–43.
  24. Chen WP, Matsunari I, Noda A, et al. Rapid scanning protocol for brain (18)F-FDG PET: a validation study. J Nucl Med 2005;46:1633–41.
  25. Lucignani G, Schmidt KC, Moresco RM, et al. Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogeneous tissue: theoretical considerations and practical procedure. J Nucl Med 1993;34:360–9.
  26. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 2000;41:661–81.
  27. Henry TR, Engel J Jr, Mazziotta JC. Clinical evaluation of interictal fluorine-18-fluordeoxyglucose PET in partial epilepsy. J Nucl Med 1993;34:1892–998.
  28. Schreckenberger M, Spetzger U, Sabri O, et al. Localisation of motor areas in brain tumour patients: a comparison of preoperative 18-FDG-PET and intraoperative cortical electrostimulation. Eur J Nucl Med 2001;28:1394–403.
  29. Herholz K, Pietrzyk U, Karbe H, et al. Individual metabolic anatomy of repeating words demonstrated by MRI-guided positron emission tomography. Neurosci Lett 1994;182:47–50.
  30. Minoshima S, Koeppe RA, Mintun MA, et al. Automated detection of the intercommissural line for stereotactic localization of functional brain images. J Nucl Med 1993;34:322–9.
  31. Graham MM, Muzi M, Spence AM, et al. The FDG lumped constant in normal human brain. J Nucl Med 2002;43:1157–66.
  32. Minoshima S, Frey KA, Koeppe RA, et al. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238–48.
  33. Frackowiak RSJ, Friston KJ, Frith CD, Dolan RJ, Mazziotta JC. Human brain function. London: Academic Press; 1997.
  34. Drzezga A, Arnold S, Minoshima S, et al. F-18 FDG-PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med 1999;40:737–46.
  35. Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999;26:1363–78.